REVUFORJ (revumenib), FDA Approved for Treatment of Patients with Acute Myeloid Leukemia and Acute Lymphoid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for REVUFORJ, a first-in-class menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation.